Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.14), $0.12 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $28 million versus the consensus estimate of $38.61 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.